Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 06 Apr 2017 Status changed from recruiting to discontinued.
- 08 Dec 2015 Planned End Date changed from 17 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.